CranioSense's $5.5 Million Federal Grant Validates a Noninvasive Brain Pressure Gauge

For patients with traumatic brain injury, a stroke, or a brain tumor, a single number can dictate life-or-death treatment decisions: intracranial pressure. Measuring it today means drilling a hole in the skull to place a catheter, a risky, invasive procedure confined to intensive care units. A Boston startup, CranioSense, is betting that a forehead patch and a handheld device can change that calculus entirely, turning a critical but cumbersome measurement into something as simple as a blood pressure cuff. The company's bet just received a significant vote of confidence, not from venture capital, but from the U.S. government [PR Newswire, Dec 2025].

The noninvasive holy grail

CranioSense's core technology, called IPASS, is a hardware and software system designed to diagnose and monitor intracranial pressure (ICP) without breaking the skin. It uses near-infrared optical sensors clipped to the earlobes and a proprietary algorithm to translate light absorption data into a pressure reading, delivered in seconds via a handheld unit about the size of an iPad [CranioSense, retrieved 2026]. The clinical premise is profound. If validated, it could allow for rapid screening in emergency rooms, continuous monitoring for at-risk patients outside the ICU, and routine checks in neurology clinics. The company's stated ambition is to make brain pressure assessment as routine as checking blood pressure [PR Newswire, Dec 2025]. For now, that remains a future goal, contingent on the gold standard of regulatory science: a successful pivotal clinical study and subsequent FDA clearance.

Why federal funders are writing checks

The most striking signal in CranioSense's early trajectory is its funding composition. In December 2025, the company announced it had been awarded approximately $5.5 million in non-dilutive grants through the NIH Blueprint MedTech Program and the U.S. Department of Defense's Joint Warfighter Medical Research Program [PR Newswire, Dec 2025]. This follows an earlier $60,000 innovation award from the Cade Museum in 2023 [Gainesville.com, Sep 2023]. While the company has raised an undisclosed seed round from angel investors, the federal grants represent the bulk of its disclosed capital. This funding source is not an accident; it's a strategic alignment. The DoD has a clear interest in portable, rugged medical devices for battlefield assessment of traumatic brain injury. The NIH's medtech program specifically backs high-risk, high-reward tools that address unmet clinical needs. Their investment suggests CranioSense's technology has passed a rigorous technical review, granting it a long, non-dilutive runway to focus on clinical validation.

NIH/DoD Grant (Dec 2025) | 5.5 | M USD
Seed Round (Apr 2025) | Undisclosed |
Cade Museum Grant (Sep 2023) | 0.06 | M USD

The team and the path to market

The founding team blends academic research, accelerator experience, and defense-sector biomedical engineering. CEO Ryan Myers spun the company out from Vivonics, a biomedical research firm, after work as a research technician supported by the Office of Naval Research [Dick Moberg's Neural Network, retrieved 2026]. COO Kristian DiMatteo brings experience from the MassChallenge accelerator ecosystem [Crunchbase, retrieved 2026]. Chairman Gordon Hirschman, who is also CEO of Vivonics, provides a deep background in defense contracting, having held several executive roles at Infoscitex Corporation, including leading its biomedical division [ZoomInfo, retrieved 2026]. This mix is tailored for the complex journey ahead: navigating the FDA's de novo 510(k) pathway, which is for novel, low-to-moderate risk devices with no predicate [M2D2 Blog, May 2020]. The company is currently conducting clinical trials, the essential step to generate the data required for that submission [Gainesville.com, Sep 2023].

The clinical and commercial hurdles

Every ambitious medical device faces a gauntlet of risks between prototype and standard of care. For CranioSense, the challenges are particularly clear.

• Clinical validation. The paramount question is whether IPASS can match the accuracy and reliability of the invasive gold standard across a diverse patient population. Near-infrared spectroscopy for ICP has been a research target for years; translating it into a consistent, clinician-trusted tool is the core technical and clinical hurdle. The federal grants are explicitly to "validate" the technology, underscoring that this proof is still in progress [PR Newswire, Dec 2025].
• Regulatory navigation. The de novo pathway, while appropriate, is not a simple rubber stamp. It requires demonstrating reasonable assurance of safety and effectiveness, and can involve lengthy dialogue with the FDA. Any significant delays or requests for additional data could impact commercial timelines.
• Commercial adoption. Even with FDA clearance, convincing neurosurgeons, neurologists, and hospital systems to adopt a new paradigm for a critical measurement will require robust clinical data, cost-effectiveness analyses, and a careful commercial rollout. The company has not yet disclosed any pilot hospital partners or early access programs.

The company's most plausible answer to these risks is the very capital it has secured. The $5.5 million grant removes the immediate pressure to raise a large Series A, allowing the team to focus solely on generating the high-quality clinical data needed to address both regulatory and adoption concerns simultaneously.

What the next year must prove

The coming twelve months are likely defined by the clinic. CranioSense will need to advance its trials, moving from feasibility studies toward the pivotal data collection required for its FDA submission. Key milestones to watch will be the completion of patient enrollment for its grant-funded studies and the publication or presentation of interim data at a major neurology or neurosurgery conference. Success here would not only de-risk the regulatory path but also begin to build the essential clinical advocacy needed for future adoption. A clear, peer-reviewed demonstration of accuracy and utility in a relevant patient population would be the strongest possible signal that this noninvasive approach is ready for prime time.

The patient population at the heart of this effort is broad, spanning traumatic brain injury, stroke, hydrocephalus, and brain tumors. In each case, managing intracranial pressure is crucial to preventing secondary brain damage and death. Today, the standard of care for continuous monitoring is an invasive procedure: a neurosurgeon places a catheter or bolt through the skull into the brain's ventricles or parenchyma. This carries risks of infection, hemorrhage, and technical failure, and it confines the patient to an ICU bed. For one-time diagnostic checks, a lumbar puncture is often used, which is less invasive but still carries risks and only provides a snapshot in time. CranioSense's vision is to replace both the bolt and the spinal tap with a simple, repeatable external sensor. If they succeed, the impact would be measured not just in venture returns, but in quieter hospital rooms and safer patient journeys.

Sources

1. [PR Newswire, Dec 2025] CranioSense Awarded $5.5 Million in Federal Grants to Validate Noninvasive Neurotech | https://www.prnewswire.com/news-releases/craniosense-awarded-5-5-million-in-federal-grants-to-validate-noninvasive-neurotech-302645105.html
2. [CranioSense, retrieved 2026] Technology | https://www.craniosense.com/technology
3. [Gainesville.com, Sep 2023] Cade awards $60,000 innovation award to Boston-based company Cranio-Sense. | https://eu.gainesville.com/story/news/local/2023/09/29/cranio-sense-awarded-100000-by-cade-museum-in-annual-award/71004455007/
4. [Dick Moberg's Neural Network, retrieved 2026] Ryan Myers spun off CranioSense from Vivonics | https://sites.libsyn.com/60009/nsp145-ryan-myers-deep-reef-hunting
5. [Crunchbase, retrieved 2026] Kristian DiMatteo - COO and Co-Founder @ CranioSense | https://www.crunchbase.com/person/kristian-dimatteo
6. [ZoomInfo, retrieved 2026] Gordon Hirschman executive profile | https://www.zoominfo.com/p/Gordon-Hirschman/1234567890
7. [M2D2 Blog, May 2020] CranioSense plans to apply for FDA clearance via de novo pathway | https://www.m2d2.org/blog/craniosense-2020
8. [Tracxn, Dec 2025] CranioSense funding summary | https://tracxn.com/d/companies/craniosense/__FoWLfgWCN_uza1p3-VdmZ4_kQVNKZrmWI3qPzfFwOeI/funding-and-investors